Investigating the AcrySof toric IOL

Article

A recent study has shown that the AcrySof toric IOL is more stable and provides better vision in cataract patients with pre-existing astigmatism, compared with an AcrySof spherical IOL.

A recent study in the Journal of Ophthalmology has shown that the AcrySof toric IOL is more stable and provides better vision in cataract patients with pre-existing astigmatism, compared with an AcrySof spherical IOL.

The research, led by Dr Edward Holland of the Cincinnati Eye Institute, University of Cincinnati, Ohio, USA investigated vision and rotational stability of the AcrySof Toric IOL in subjects with cataracts and pre-existing corneal astigmatism in comparison to its spherical equivalent.

There were 517 participants in the 1-year randomized, subject-masked, parallel-group, multicentre trial, 256 of whom had the toric implant and 261 had the control IOL implant. The results demonstrated that the toric lens gave better visual acuity - 20/20 or better - for both corrected and uncorrected vision. The mean absolute residual refractive cylinder was lower for the toric lens and the mean rotation was less than 4º. Additionally, the percentage of patients who were spectacle-free after six months was higher for those with the toric implant in comparison with the control group.

Based on the results of the study the researchers concluded that the favourable efficacy, rotational stability, distance vision spectacle freedom and safety results supports the use of Alcon's AcrySof Toric IOL for patients with cataracts and corneal astigmatism.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.